IGF1R and cancer: Two main strategies for IGF-1R-targeted therapy (namely, blocking anti-IGF-1R antibodies and small molecule inhibitors of tyrosine kinase receptors) have been actively pursued over the past decade, resulting in various preclinical and clinical studies in diverse cancers, which were reviewed periodically [22]–[36].